We aim to highlight a diagnostic approach toward a new clinical entity of de Novo AML with BCR/ABL1 fusion gene described by WHO in 2016 from CML with BCR/ABL1 gene, which can be challenging in some clinical scenarios. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.